Free Trial
NASDAQ:PHAT

Phathom Pharmaceuticals Q2 2023 Earnings Report

Phathom Pharmaceuticals logo
$8.35 -0.19 (-2.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.40 +0.05 (+0.59%)
As of 08/1/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals EPS Results

Actual EPS
-$0.84
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Phathom Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Phathom Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Phathom Pharmaceuticals' Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Phathom Pharmaceuticals Earnings Headlines

Is America’s Everything Bubble About to Burst?
On July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushing America’s debt-to-GDP ratio to 175%. Top investors are warning of an epic bubble bursting soon. A free guide reveals how to shield your 401(k), savings, and portfolio before the collapse.
Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance
See More Phathom Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals (NASDAQ:PHAT), biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

View Phathom Pharmaceuticals Profile

More Earnings Resources from MarketBeat